FAQs on H.E.L.P. apheresis
What preliminary assessments are carried out before a patient is admitted for treatment?
We have set up a website to serve as the initial point of contact, which features information and a questionnaire that the potential patient can use to provide us with some basic details to start with. If a patient meets the requirements (these are clarified using a questionnaire), they are first placed on a waiting list. As soon as places are available, a detailed patient interview is conducted and the requisite laboratory tests (assessment) carried out. The aim here is, among other things, to identify the severity of the patient’s symptoms and clarify whether the prerequisites for treatment using H.E.L.P. apheresis – in terms of the intended purpose of the Plasmat Futura device – are fulfilled.
Who bears the costs?
The costs of around CHF 2,000 per treatment are currently borne by the patient. Of course, the patient can apply to their health insurance for coverage of the costs.
Is this treatment recognized by the medical authorities here in Switzerland?
H.E.L.P. apheresis is recognized and the cost rates regulated in Switzerland for patients with homozygous familial hypercholesterolemia. For all other indications for H.E.L.P. apheresis, there are currently no fixed rates and cover by the health insurance fund depends on each individual case. Of course, we support the patient with applying to their health insurance company.
Which symptoms of Long Covid does this therapy help with?
The symptoms of Long Covid vary greatly. Any organ system can be affected. Treatments carried out to date indicate that many of these symptoms can be successfully treated by improving microcirculation.
Are there also risks involved in the treatment? If so, what are they?
H.E.L.P. apheresis is generally very well tolerated and has few complications. But, as with any treatment, it does have risks and side effects. However, these are very rare and are easily treated. For example, the patient may have hematomas at the injection sites, a short-term vasovagal reaction (passing out) or temporary fatigue.
Are there any studies available on H.E.L.P. apheresis?
Website in deutsch